Merck & Co., Inc: Pneumococcal Infections trials

The registry lists 43 Pneumococcal Infections studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 40 have results posted.

Phase 1 6Phase 2 7Phase 3 31Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)RecruitingNCT07300267Phase 1
• A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)CompletedNCT06177912Phase 3Results posted
• Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)CompletedNCT05696080Phase 3Results posted
• Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)CompletedNCT05633992Phase 3Results posted
• Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)CompletedNCT05569954Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)CompletedNCT05464420Phase 3Results posted
• Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)CompletedNCT05425732Phase 3Results posted
• Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)CompletedNCT05393037Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)CompletedNCT05158140Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)CompletedNCT04665050Phase 1Results posted
• Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)CompletedNCT04633226Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)CompletedNCT04384107Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)CompletedNCT04031846Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)CompletedNCT04016714Phase 3Results posted
• Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)CompletedNCT03950856Phase 3Results posted
• Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)CompletedNCT03950622Phase 3Results posted
• Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)CompletedNCT03921424Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)CompletedNCT03893448Phase 3Results posted
• Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)CompletedNCT03885934Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)CompletedNCT03848065Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)CompletedNCT03731182Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)CompletedNCT03692871Phase 3Results posted
• A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedNCT03620162Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)CompletedNCT03615482Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)CompletedNCT03565900Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)CompletedNCT03547167Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)CompletedNCT03480802Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)CompletedNCT03480763Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)CompletedNCT02987972Phase 2Results posted
• Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)CompletedNCT02573181Phase 2Results posted
• Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)CompletedNCT02547649Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)CompletedNCT02531373Phase 1/2Results posted
• Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)CompletedNCT02260882Phase 4Results posted
• Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)CompletedNCT02225587Phase 3Results posted
• Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)CompletedNCT02037984Phase 1/2Results posted
• A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)CompletedNCT01734239Phase 3Results posted
• The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)CompletedNCT01513551Phase 2Results posted
• A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)CompletedNCT01215188Phase 2Results posted
• Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)CompletedNCT01215175Phase 1Results posted
• Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)CompletedNCT00560950Phase 3Results posted
• ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)CompletedNCT00535730Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)CompletedNCT00496093Phase 3
• A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)CompletedNCT00127153Phase 3